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Intraluminal brachytherapy is still an important part of 
brachytherapy procedures done especially in palliative 
patients. But large differences between countries over the 
world are observed. It is not clear how the future of 
intraluminal brachytherapy will look like. Brachytherapy is 
one of the most efficient methods in overcoming difficulties 
in breathing that is caused by endobronchial obstruction in 
palliative treatment of bronchus cancer. Depending on the 
location of the lesion in some cases brachytherapy is a 
treatment of choice. Because of uncontrolled local or 
recurrent disease, patients may have significant symptoms 
such as: cough, dyspnea, haemoptysis, obstructive 
pneumonia or atelectasis. Efforts to relieve this obstructive 
process are worthwhile, because patients may experience 
improved quality of their life. Brachytherapy plays a limited 
but specific role in definitive treatment with curative intent 
in selected cases of early endobronchial disease as well as in 
the postoperative treatment of small residual peribronchial 
disease. Various methods of palliation have been used in an 
attempt to improve patients’ quality of life and to provide 
near normal, if not normal, swallowing until death occurs 
because of progressive esophageal cancer. Endoesophageal 
brachytherapy makes it possible to use high doses of 
radiation to the tumor itself with concurrent protection of 
adjoining healthy tissues due to the rapid fall in the dose 
with the square of the distance from the center of the dose. 
The above treatment also leads to a smaller proportion of 
late radiation complications. The aim of palliative 
brachytherapy is to reduce dysphagia, diminish pain and 
bleeding, and to improve the patient’s well-being. Palliative 
treatment options for bile duct cancer or pancreas cancer 
remain limited due to the large number of patients with 
advanced disease at the time of diagnosis. Radical surgery is 
possible in less than 10-15% of these cases. Unrespectable 
bile duct or pancreas cancers are very difficult to treat with 
external beam therapy alone due to the proximity of 
adjacent normal organs and the high doses required to 
effectively irradiating these neoplasms. Although the results 
available in the literature are somewhat contradictory as 
regards the possible use of intraluminal brachytherapy in a 
curative setting, some evidence indicates that intraluminal 
brachytherapy can add something to the treatment of 
unresectabbe extrahepatic bile duct and pancreatic cancers 
if a proper subset of patients is identifled and a rational and 
aggressive scheme of mubtimodality treatment is designed. 
High rate of advanced cases affects the enrollment of 
brachytherapy (BT) into treatment of bile duct cancers. 
Indications for brachytherapy include all malignant strictures 
of the bile duct which can be cannulated. Intraluminal 
brachytherapy (ILBT) is an important component in the 
multimodality approach to bile duct cancers. The objective 
of this treatment is to deliver a high local dose of radiation 
to the tumor while sparing surrounding healthy tissues. The 
treatment can be safely adapted for right and left hepatic 
duct as well as for common bile duct lesions. The standard of 
care in rectal cancer is still surgery. For limited size rectal 
cancer (T1, small T2), brachytherapy alone offers an 
alternative to radical surgery and leads to excellent results 
without major morbidity. In advanced rectal cancer, a 
proportion of patients can achieve complete clinical response 
after external beam chemoradiotherapy (EBCRT) that can be 
demonstrated on MRI after neoadjuvant treatment. Chosen 
summarized indications, treatment schedules, results and 
complications are discussed in the following presentation. 
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Big data is a buzzword. But what is Big Data? And what can 
we do with Big Data in radiotherapy?  
In this teaching lecture we will discuss what Big Data is and 
what kind of data a modern radiotherapy center produces. 
Innovative technology to extract, store and process these Big 
Data are becoming available and will be discussed.  
Big Data is often seen as tremendously promising and is 
predicted to change health care radically, but at this point in 
time is mostly a challenge as we keep accumulating data 
without a clear path to clinical applications while privacy 
concerns are on the rise. Methods and examples how we go 
from data to making a difference in lives of cancer patients 
will be presented. As will the methods to do this in a way 
that preservers the privacy of patients.  
Finally the future of Big Data is drawn and the case will be 
made that more data is not always the answer if we do not 
have a Big Machine ready to learn from these data. 
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Independent dosimetry audit is an essential component of 
best practice radiotherapy. However the value and concepts 
are not always fully understood. This lecture will review the 
methods and approaches of dosimetry audit and discuss its 
clinical importance. Examples will be given from a range of 
previously completed audits as well as considering what is 
needed in the role of audit in the implementation of new 
technologies. 
Drawing on experience from both external beam and 
brachytherapy dosimetry audits worldwide, we will review 
the key elements of audit design, implementation and 
analysis, including: choice of phantoms and detectors, 
remote or on-site visits, efficiency and efficacy of the audit 
methodology, and reporting and feedback considerations. 
The learning outcomes of this teaching lecture are: 
· to understand why audit can improve safety, quality and 
best practice radiotherapy;  
· to know how to choose appropriate methodology for audit 
and understand the outcomes;  
· to appreciate the scientific, philosophical and legal 
reasoning for dosimetry audit. 
 
 
 
 
